Marta Fernandez-Arquillue, Samuel J Martinez-Dominguez, Ángel Lanas
{"title":"A look into adverse renal effects of proton pump inhibitors.","authors":"Marta Fernandez-Arquillue, Samuel J Martinez-Dominguez, Ángel Lanas","doi":"10.1080/14740338.2026.2753935","DOIUrl":"10.1080/14740338.2026.2753935","url":null,"abstract":"","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-4"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hao Xie, Rui Dai, Yixun Shi, Xinyu Du, Zhiqing Xu, Xiaoli Du, Gang Chen, Bin Zhao
{"title":"Analysis of risk factors and development of a predictive model for significant serum creatinine elevation in patients administered SGLT2 inhibitor in a real-world clinical setting in China.","authors":"Hao Xie, Rui Dai, Yixun Shi, Xinyu Du, Zhiqing Xu, Xiaoli Du, Gang Chen, Bin Zhao","doi":"10.1080/14740338.2025.2569123","DOIUrl":"10.1080/14740338.2025.2569123","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are widely used, but may lead to significant serum creatinine elevation ( > 30%), posing a risk of acute kidney injury.</p><p><strong>Research design and methods: </strong>A retrospective analysis was conducted using data from 3,720 hospitalized patients who received SGLT2i between 2014 and 2023. Patients were divided into two groups based on creatinine elevation ( > 30%). Univariate and multivariate logistic regression analyses were performed to identify risk factors, and a predictive model was constructed. The dataset of 1,040 patients from 2024 serves as validation data.</p><p><strong>Results: </strong>Significant serum creatinine elevation ( > 30%) occurred in 6.67% of patients. Multivariate analysis identified nine risk factors: female sex, age ≥70 years, elevated admission serum creatinine, low admission plasma albumin, heart failure, and concomitant use of nephrotoxic antimicrobials, biologics, diuretics, or antiarrhythmic drugs. The predictive model demonstrated good discrimination (area under curve: 0.815) and calibration (<i>p</i> = 0.717), with consistent performance in the validation cohort (area under curve: 0.777).</p><p><strong>Conclusions: </strong>This study developed a reliable predictive model, highlighting key risk factors. The model can assist clinicians in early identification and monitoring of patients at risk, potentially reducing adverse renal outcomes and hospital stays. Further prospective studies are needed to validate and refine the model.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2183-2190"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145344471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mehmet Akif Suludere, Jamie Monica Alberga, Gwenny Verstappen, Bert van der Vegt, Marcel Nijland, Arjan Vissink, Hendrika Bootsma, Konstantina Delli
{"title":"Safety and efficacy of currently used drug therapies for treatment of lymphomas in patients with Sjögren's disease, a scoping review.","authors":"Mehmet Akif Suludere, Jamie Monica Alberga, Gwenny Verstappen, Bert van der Vegt, Marcel Nijland, Arjan Vissink, Hendrika Bootsma, Konstantina Delli","doi":"10.1080/14740338.2026.2654765","DOIUrl":"10.1080/14740338.2026.2654765","url":null,"abstract":"<p><strong>Introduction: </strong>Sjögren's disease (SjD) carries an increased risk of B-cell lymphoma, yet drug treatment strategies are largely extrapolated from general lymphoma care. This study summarizes available evidence on the efficacy and safety of drug therapies in SjD-associated lymphomas.</p><p><strong>Areas covered: </strong>A PubMed and Embase search (January 1995-August 2025) identified studies evaluating the efficacy and safety of pharmacologic treatment for SjD-associated non-Hodgkin B-cell lymphomas (English language, ≥5 patients). Rituximab (anti-CD20) monotherapy achieved reliable early disease control in localized, low-burden lymphoma with limited toxicity. In more disseminated or aggressive lymphoma types, particularly diffuse large B-cell lymphoma, immunochemotherapy (rituximab plus chemotherapy) remains standard. In indolent disease, immunochemotherapy combination regimens can improve lymphoma control. However, regimen-specific safety data are limited and inconsistently reported.</p><p><strong>Expert opinion: </strong>Current evidence supports a pragmatic, individualized approach. Rituximab remains the foundation of SjD-associated lymphoma therapy, typically combined with chemotherapy. However, current evidence is limited by small, heterogeneous cohorts, with pooled reporting across lymphoma types/regimens and limited safety reporting. Prospective SjD-specific studies, with regimen-level reporting of efficacy and safety are needed. Uniform endpoints that capture both hematologic and autoimmune activity, and lymphoma-type stratification should be applied.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2015-2022"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Henan Qin, Yibin Teng, Peiyao Yu, Zhen Ning, Jiwei Liu
{"title":"Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database.","authors":"Henan Qin, Yibin Teng, Peiyao Yu, Zhen Ning, Jiwei Liu","doi":"10.1080/14740338.2025.2489529","DOIUrl":"10.1080/14740338.2025.2489529","url":null,"abstract":"<p><strong>Background: </strong>EGFR and HER2 dual TKIs have been approved for the treatment of advanced breast cancer in patients who are HER2-positive for second and/or third-line treatment. However, there is a lack of attention to the cardiovascular adverse events (AEs) caused by EGFR and HER2 dual TKIs.</p><p><strong>Research design and methods: </strong>We analyzed data spanning between March 2007 and June 2024 using the FAERS database and the reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network to perform disproportionality analysis.</p><p><strong>Results: </strong>Compared with non-cardiovascular AEs, cardiovascular AEs were associated with more severe clinical outcomes, such as higher rates of hospitalization, life-threatening events, disability, and death. Our analysis revealed that lapatinib had a higher-than-expected reporting rate for three SMQs, including cardiac failure, embolic and thrombotic events, and cardiomyopathy. No significant cardiovascular signals were observed for neratinib.</p><p><strong>Conclusion: </strong>Disproportionality analysis results revealed a positive signal for cardiac failure, embolic and thrombotic events, and cardiomyopathy of lapatinib, and no positive signal for neratinib. We should pay attention to high-risk signals in clinical practice and monitor them appropriately.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2095-2103"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Trends in the use of sodium-glucose cotransporter-2 inhibitors and characteristics of adverse event reporting in patients with heart failure in Japan: reports from the medical administration database and the adverse event reporting database.","authors":"Kazuya Sato, Kei Kawada, Tomoaki Ishida, Toru Kubo, Miyata Koji, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Mitsuhiro Goda, Keisuke Ishizawa","doi":"10.1080/14740338.2025.2539543","DOIUrl":"10.1080/14740338.2025.2539543","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is a global health issue with a high prevalence in aging populations. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce HF-related hospitalizations and mortality; however, their adverse drug events (ADEs) require further evaluation.</p><p><strong>Research design and methods: </strong>Using the Japan Medical Data Center and Japanese Adverse Drug Event Report (JADER) databases, we analyzed prescribing trends and ADE risk factors. Multivariate logistic regression assessed associations between patient characteristics and ADEs, adjusting for age, sex, medication use, and comorbidities. Decision tree analyses stratified ADE risks.</p><p><strong>Results: </strong>SGLT2 inhibitor prescriptions increased from 1.63% (2018) to 9.08% (2022), with a notable rise in 2021. JADER analysis showed an increasing number of ADE reports, primarily dehydration, urinary tract infections, and renal impairment. Decision tree analyses identified risk factors: dehydration (age ≥80 years, tolvaptan use), urinary tract infection (female sex, renal dysfunction), and renal impairment (angiotensin receptor-neprilysin inhibitor use, history of renal dysfunction).</p><p><strong>Conclusions: </strong>Personalized risk assessment and monitoring are crucial for optimizing SGLT2 inhibitor therapy, particularly in older patients with HF and renal impairment.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2163-2173"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age.","authors":"Kazuhiro Yamamoto, Yusuke Naito, Sakurako Watanabe","doi":"10.1080/14740338.2025.2519835","DOIUrl":"10.1080/14740338.2025.2519835","url":null,"abstract":"<p><strong>Background: </strong>The sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin is approved in Japan for the treatment of heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) and HF with preserved left ventricular ejection fraction (HFpEF). We conducted a post-marketing surveillance study of empagliflozin for HF in Japan.</p><p><strong>Research design & methods: </strong>This was a 1-year prospective, multicenter, observational study of patients with chronic HF who had not previously received empagliflozin. The primary endpoint was incidence of adverse drug reactions (ADRs). Prespecified effectiveness endpoints were all-cause death, cardiovascular (CV) death, and hospitalization for HF (HHF).</p><p><strong>Results: </strong>1,166 patients were included (61.0% male, mean age 74.9 years). At baseline, mean left ventricular ejection fraction was 49.0%, mean body mass index was 24.2 ± 4.6 kg/m<sup>2</sup>, and 34.2% had type 2 diabetes. ADRs occurred in 61 (5.2%) patients overall, 5.8% of those aged ≥ 75 years, 6.2% of those aged 65 to < 75 years, and 2.2% of those aged < 65 years. Incidences of all-cause death, CV death, and HHF were 3.0, 0.9, and 2.5 per 100 PY, respectively.</p><p><strong>Conclusions: </strong>In this 1-year post-marketing surveillance study, empagliflozin was generally well-tolerated in patients with HF in Japan.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier is NCT05262764.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2153-2161"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-term safety of treatment of hemophilia A: a comprehensive review.","authors":"Johnny Mahlangu","doi":"10.1080/14740338.2026.2742174","DOIUrl":"10.1080/14740338.2026.2742174","url":null,"abstract":"<p><strong>Introduction: </strong>Hemophilia A is an inherited bleeding disorder caused by factor VIII (FVIII) deficiency, resulting in recurrent bleeding and progressive joint damage. Treatment has expanded beyond FVIII replacement to extended-half-life products, non-factor therapies, rebalancing agents, and gene therapy. These advances improve outcomes but introduce distinct long-term safety considerations.</p><p><strong>Areas covered: </strong>This review evaluates long-term safety evidence from pivotal trials, extension studies, real-world registries, and recent international congress reports. It examines standard- and extended-half-life FVIII concentrates, efanesoctocog alfa, emicizumab, emerging rebalancing agents targeting natural anticoagulant pathways, and adeno-associated virus vector-based gene therapies.</p><p><strong>Expert opinion: </strong>Established hemophilia A treatments generally have favorable long-term safety profiles and reduce treatment burden; however, mature safety data remain limited for newer agents. Inhibitor development remains the principal complication of FVIII replacement. Non-factor and rebalancing therapies carry potential thrombotic risks requiring appropriate monitoring. Gene therapy may provide durable FVIII expression after a single administration but raises concerns regarding hepatotoxicity, durability of expression, and uncertain long-term effects. Continued pharmacovigilance and individualized treatment selection are therefore essential as therapeutic options expand.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-16"},"PeriodicalIF":3.0,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-world data analysis of topotecan in combination with Bevacizumab or CycloPhosphamide in the FDA adverse event reporting system (FAERS) database.","authors":"Huihui Chen, Guobiao Zhuang, Shihao Hong, Jing Wu","doi":"10.1080/14740338.2025.2488240","DOIUrl":"10.1080/14740338.2025.2488240","url":null,"abstract":"<p><strong>Background: </strong>The main purpose of this study is to observe and detect adverse reactions to the combination of topotecan, bevacizumab and cyclophosphamide, to learn more about possible adverse drug reactions (ADRs) and to help doctors make the right medication decisions and treatment plans.</p><p><strong>Research design and methods: </strong>Adverse event signals were detected and quantified using data from the U.S. Food and Drug Administration's Adverse Event Reporting System using reporting ratios, proportions of reports (PRR), Bayesian Confidence Propagation Neural Networks (BCPN), and empirical Bayesian Geometric Mean (EBGM). Subgroup analyses were performed to compare adverse events associated with topotecan alone.</p><p><strong>Results: </strong>The analysis of FAERS data revealed a total of 1,789 primary suspected adverse events (PS AEs) linked to topotecan. The Weibull shape parameter (β) for females was lower than for males across all age groups, indicating a potentially higher susceptibility to the adverse effects of topotecan in female patients.</p><p><strong>Conclusions: </strong>This study proved several expected and new adverse drug reactions associated with the combination of topotecan, bevacizumab, and cyclophosphamide. While some ADRs, such as neutropenia and anemia, align with the known adverse profile of topotecan, the detection of novel signals, including potential gender-based differences in drug response, warrants further investigation.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1857-1868"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reports (FAERS) for drug-induced sinusitis.","authors":"Enze Wang, Yingxuan Sun, He Zhao, Zhiwei Cao","doi":"10.1080/14740338.2025.2484474","DOIUrl":"10.1080/14740338.2025.2484474","url":null,"abstract":"<p><strong>Background: </strong>Drug-induced sinusitis has been widely reported as an adverse drug reaction in recent years, yet the pharmacogenetic mechanisms and risk factors associated with sinusitis remain elusive.</p><p><strong>Objective: </strong>We aimed to identify the major drugs reported in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) in relation to sinusitis and to analyze their pharmacogenetic mechanisms through drug target analysis.</p><p><strong>Methods: </strong>We conducted a review of the publicly available FAERS database from 2004 to the third quarter of 2023. We extracted genetic tools corresponding to each drug, utilized colocalization analysis, Mendelian randomization (MR) analysis, and cross-tissue drug target analysis to predict the impact of drug targets on sinusitis.</p><p><strong>Results: </strong>Following the validation of drug-related risks, a total of 13 medications were ultimately identified, including TNF inhibitors: pomalidomide (ROR: 14.77), certolizumab pegol(ROR: 8.21), etanercept (ROR: 7.961), lenalidomide (ROR: 6.998), adalimumab (ROR: 6.677), infliximab (ROR: 3.939); C4B-targeted drugs: human immunoglobulin G (ROR:3.846) and other risk drugs were commonly reported. Co-localization analysis and MR analysis suggests associations between TNF, C4B, and LTA and sinusitis.</p><p><strong>Conclusion: </strong>We demonstrated the risk of sinusitis associated with 13 drugs, including pomalidomide, and the impact of TNF and C4B drugs on sinusitis, which provides guidance for the use of related drugs and the prevention of sinusitis.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1997-2005"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuting Wang, Jingping Zheng, Zhenpo Zhang, Haiyan Mai, Ling Su
{"title":"Peripheral neuropathies induced by BRAF+MEK inhibitor combinations: a real-world study based on FAERS database 2011-2022.","authors":"Yuting Wang, Jingping Zheng, Zhenpo Zhang, Haiyan Mai, Ling Su","doi":"10.1080/14740338.2025.2529428","DOIUrl":"10.1080/14740338.2025.2529428","url":null,"abstract":"<p><strong>Background: </strong>BRAF/MEK inhibitors (BRAFi+MEKi) like may cause peripheral neuropathies (PN). This study analyzes FAERS data to assess PN signals across BRAFi+MEKi combinations.</p><p><strong>Research design and methods: </strong>Disproportionality analysis was conducted to quantify the signals of BRAFi+MEKi-associated PN on FAERS database from January 2011 to December 2022. Additionally, we examined the onset times and prognosis of BRAFi+MEKi-associated PN.</p><p><strong>Results: </strong>A total of 268 reports of BRAFi+MEKi-associated PN were identified in the study, with a median age range of 60.00 to 69.00 years. All three combination therapies exhibited positive signals for PN, and notably, Encorafenib and Binimetinib (E+B) displayed the strongest association with PN (ROR 3.05[2.47,3.76], IC1.57[1.26]). The associations between PN and different BRAFi+MEKi combinations remained persisted in the gender and age stratification analysis, with all three combination therapies showing an elevated number of disproportionality signals in males compared to females.</p><p><strong>Conclusion: </strong>According to our findings, BRAFi+MEKi-associated PN tends to occur several months after initiation and may lead to serious outcomes. Male sex is more likely to be a risk factor associated with PN. Prompt identification and intervention for BRAFi+MEKi-associated PN are crucial, and additional fundamental research is required to validate the underlying mechanism as observed in our study.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1927-1934"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}